Communiqué de presse Archives

Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox®, its blood based colorectal cancer test

By Novigenix|2018-03-19T11:43:16+02:0015 März 2017|Allgemein|

Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold

Novigenix publishes multi-center study of Colox® in Clinical Cancer Research

By Novigenix|2018-03-09T12:06:38+02:009 Mai 2016|Allgemein|

Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with

Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer

By Sebastien|2018-03-09T14:12:45+02:0012 Februar 2015|Communiqué de presse, Communiqué de presse, Communiqué de presse|

LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox